|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.27 USD | +1.52% |
|
+1.69% | +8.56% |
| 06:44pm | Can Nvidia Do It Again? | |
| 06:21pm | Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 4.87TCr | 5.93TCr | 6.01TCr | 6.42TCr | 6.5TCr | |||||
Total Revenues | 4.87TCr | 5.93TCr | 6.01TCr | 6.42TCr | 6.5TCr | |||||
Cost of Goods Sold, Total | 1.32TCr | 1.72TCr | 1.59TCr | 1.47TCr | 1.48TCr | |||||
Gross Profit | 3.55TCr | 4.21TCr | 4.42TCr | 4.95TCr | 5.02TCr | |||||
Selling General & Admin Expenses, Total | 940.3Cr | 966.9Cr | 988.4Cr | 1.01TCr | 1.01TCr | |||||
R&D Expenses | 1.02TCr | 1.18TCr | 1.83TCr | 1.45TCr | 1.56TCr | |||||
Other Operating Expenses, Total | 1.96TCr | 2.15TCr | 2.82TCr | 2.46TCr | 2.57TCr | |||||
Operating Income | 1.59TCr | 2.06TCr | 1.6TCr | 2.49TCr | 2.45TCr | |||||
Interest Expense, Total | -81Cr | -96Cr | -114.6Cr | -127.1Cr | -135.7Cr | |||||
Interest And Investment Income | 3.6Cr | 31Cr | 36Cr | 42Cr | 34Cr | |||||
Net Interest Expenses | -77Cr | -65Cr | -78Cr | -86Cr | -101.4Cr | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | -30Cr | -24Cr | -37Cr | -23Cr | -32Cr | |||||
Other Non Operating Income (Expenses) | 26Cr | 52Cr | 42Cr | 29Cr | 20Cr | |||||
EBT, Excl. Unusual Items | 1.5TCr | 2.02TCr | 1.52TCr | 2.41TCr | 2.33TCr | |||||
Restructuring Charges | -87Cr | -67Cr | -93Cr | -89Cr | -255.1Cr | |||||
Merger & Related Restructuring Charges | -170.4Cr | - | -1.14TCr | -345.6Cr | -8.3Cr | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 194Cr | -141.9Cr | 34Cr | 1.4Cr | 37Cr | |||||
Asset Writedown | -28Cr | -160Cr | -78Cr | - | - | |||||
Legal Settlements | - | - | -57Cr | - | - | |||||
Other Unusual Items | -26Cr | -7.5Cr | - | 17Cr | - | |||||
EBT, Incl. Unusual Items | 1.39TCr | 1.64TCr | 188.9Cr | 1.99TCr | 2.11TCr | |||||
Income Tax Expense | 152.1Cr | 191.8Cr | 151.2Cr | 280.3Cr | 280.4Cr | |||||
Earnings From Continuing Operations | 1.24TCr | 1.45TCr | 38Cr | 1.71TCr | 1.83TCr | |||||
Earnings Of Discontinued Operations | 70Cr | - | - | - | - | |||||
Net Income to Company | 1.31TCr | 1.45TCr | 38Cr | 1.71TCr | 1.83TCr | |||||
Minority Interest | -1.3Cr | -70L | -1.2Cr | -1.6Cr | -90L | |||||
Net Income - (IS) | 1.3TCr | 1.45TCr | 36Cr | 1.71TCr | 1.83TCr | |||||
Net Income to Common Incl Extra Items | 1.3TCr | 1.45TCr | 36Cr | 1.71TCr | 1.83TCr | |||||
Net Income to Common Excl. Extra Items | 1.23TCr | 1.45TCr | 36Cr | 1.71TCr | 1.83TCr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.16 | 5.73 | 0.14 | 6.76 | 7.3 | |||||
Basic EPS - Continuing Operations | 4.88 | 5.73 | 0.14 | 6.76 | 7.3 | |||||
Basic Weighted Average Shares Outstanding | 253Cr | 253.2Cr | 253.7Cr | 253.2Cr | 250.2Cr | |||||
Net EPS - Diluted | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 | |||||
Diluted EPS - Continuing Operations | 4.86 | 5.71 | 0.14 | 6.74 | 7.28 | |||||
Diluted Weighted Average Shares Outstanding | 253.8Cr | 254.2Cr | 254.7Cr | 254.1Cr | 250.7Cr | |||||
Normalized Basic EPS | 3.71 | 4.98 | 3.75 | 5.94 | 5.82 | |||||
Normalized Diluted EPS | 3.7 | 4.96 | 3.74 | 5.92 | 5.81 | |||||
Dividend Per Share | 2.6 | 2.76 | 2.92 | 3.08 | 3.24 | |||||
Payout Ratio | 50.66 | 48.3 | 2.04T | 45.8 | 44.79 | |||||
American Depositary Receipts Ratio (ADR) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.9TCr | 2.44TCr | 1.97TCr | 2.91TCr | 2.91TCr | |||||
EBITA | 1.75TCr | 2.26TCr | 1.8TCr | 2.73TCr | 2.73TCr | |||||
EBIT | 1.59TCr | 2.06TCr | 1.6TCr | 2.49TCr | 2.45TCr | |||||
EBITDAR | 1.93TCr | 2.47TCr | 2TCr | 2.95TCr | 2.95TCr | |||||
Effective Tax Rate - (Ratio) | 10.96 | 11.66 | 80.04 | 14.06 | 13.31 | |||||
Current Domestic Taxes | 6.1Cr | 232.2Cr | 98Cr | 93Cr | 40Cr | |||||
Current Foreign Taxes | 127.3Cr | 116.4Cr | 243.5Cr | 312.3Cr | 407.2Cr | |||||
Total Current Taxes | 133.4Cr | 348.6Cr | 341.1Cr | 405.2Cr | 447.5Cr | |||||
Deferred Domestic Taxes | 26Cr | -163.9Cr | -166.6Cr | -146.1Cr | -158.8Cr | |||||
Deferred Foreign Taxes | -7.7Cr | 7.1Cr | -23Cr | 21Cr | -8.3Cr | |||||
Total Deferred Taxes | 19Cr | -156.8Cr | -189.9Cr | -124.9Cr | -167.1Cr | |||||
Normalized Net Income | 939.08Cr | 1.26TCr | 951.49Cr | 1.5TCr | 1.46TCr | |||||
Non-Cash Pension Expense | 1.7Cr | -10Cr | -40Cr | -51Cr | -54Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 200Cr | 220Cr | 230Cr | 240Cr | 230Cr | |||||
Selling and Marketing Expenses | 200Cr | 220Cr | 230Cr | 240Cr | 230Cr | |||||
Research And Development Expense From Footnotes | 1.22TCr | 1.35TCr | 3.05TCr | 1.79TCr | 1.58TCr | |||||
Net Rental Expense, Total | 34Cr | 33Cr | 34Cr | 35Cr | 42Cr | |||||
Imputed Operating Lease Interest Expense | 6.5Cr | 7.72Cr | 9.11Cr | 9.49Cr | 10Cr | |||||
Imputed Operating Lease Depreciation | 28Cr | 26Cr | 25Cr | 25Cr | 32Cr | |||||
Stock-Based Comp., Other (Total) | 48Cr | 54Cr | 64Cr | 76Cr | 82Cr | |||||
Total Stock-Based Compensation | 48Cr | 54Cr | 64Cr | 76Cr | 82Cr |
- Stock Market
- Equities
- MRK Stock
- Financials Merck & Co., Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















